<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745264</url>
  </required_header>
  <id_info>
    <org_study_id>CL-033-I-04</org_study_id>
    <nct_id>NCT00745264</nct_id>
  </id_info>
  <brief_title>Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise</brief_title>
  <official_title>Multi-Centre, Open-Label, Two Segment, Parallel Group Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDEA AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDEA AG</source>
  <brief_summary>
    <textblock>
      -  Comparison of the plasma PK after single use of 100 mg ketoprofen from Diractin®. 50 mg
           applied on 2 major joints to

        -  400 mg ketoprofen from Diractin® (100 mg applied to 4 joints - overexposure)

        -  100 mg and 400 mg ketoprofen from Diractin® used concomitant with heat application

        -  100 mg and 400 mg ketoprofen from Diractin® used concomitant with moderate exercise
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pharmacokinetic</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Ketoprofen from Diractin to 4 joints</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 and 400 mg Ketoprofen used concomittant with heat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 and 400 mg Ketoprofen concomittant with moderate exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ketoprofen to 2 joints</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diractin</intervention_name>
    <description>100 mg Ketoprofen to 2 joints</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diractin</intervention_name>
    <description>400 mg ketoprofen to 4 joints</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diractin</intervention_name>
    <description>100 and 400 mg Ketoprofen used concomittant with heat</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diractin</intervention_name>
    <description>100 and 400 mg Ketoprofen concomittant with moderate exercise</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All of the following criteria have to be met to include a subject in the study:

               -  Understands nature and provision of the study

               -  Have been informed about the study by the investigator and gave signed and dated
                  informed consent prior to participation

               -  Male and female subjects

               -  Age 18-55 years

               -  Subjects in good health as determined by the Investigator

               -  Woman of childbearing potential using reliable methods of contraception with a
                  low failure rate (i.e. less than 1% per year), e.g. implants, injectables,
                  combined oral contraceptives, reliable intrauterine-devices, vasectomised/
                  infertile partner or surgically sterile (uterus removed or both tubes tied) or
                  postmenopausal (at least 2 years without periods)

        Exclusion Criteria:

          -  4.2.1 General Exclusion Criteria

               -  Investigator or any other team member involved directly or indirectly in the
                  conduct of the clinical trial

               -  Subjects who are inmates of psychiatric wards, prisons, or other state
                  institutions

               -  Participation in another clinical trial within the last 30 days

               -  Not willing to refrain from exposing target areas after treatment to excessive
                  ultraviolet light (solar radiation or solarium)

               -  Pregnancy or lactation

        4.2.2 Medical History Related Exclusion Criteria

          -  Known hypersensitivity or allergy (including photoallergy) to NSAID´s including
             ketoprofen, and ingredients used in pharmaceutical products

          -  Alcohol or drug abuse

          -  Malignancy within the past 2 years

          -  Skin lesions, dermatological diseases or tattoo in the treatment area

          -  Major surgery 3 months before enrolment

          -  Impaired haematopoesis and coagulation

          -  Gastric and duodenal ulcer and gastrointestinal bleedings

          -  Systemic lupus erythematodes, mixed connective tissue disease

          -  Major heart disease / uncontrolled hypertension

          -  Hepatic failure with ALT and/or AST &gt; 2.0 ULN

          -  Renal failure with serum creatinine levels &gt; 1.5 milligrams/deciliter (mg/dL)

          -  Varicosis, thrombophlebitis and other vascular disorders of the lower extremities

          -  Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the
             musculo-sceletal system of the lower limbs

          -  HIV - Infection

          -  Blood donation one (1) month before screening and during study

          -  Hepatitis B and C

          -  Asthma bronchiale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egbert Seidel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>X-pert Med GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>X-pert Med GmbH</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm Interantional GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>March 19, 2009</last_update_submitted>
  <last_update_submitted_qc>March 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2009</last_update_posted>
  <keyword>heat</keyword>
  <keyword>exercise</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

